Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06208150 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
A Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 795
- Enrollment target
- 20
- Study locations
NCT06208150 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 795 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06208150, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 795 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Talquetamab
- DRUG Elotuzumab
Study Locations (20)
Maryland
- Luminis Health Center for Cancer and Blood Disorders - Annapolis
- University of Maryland School of Medicine - Baltimore
- The Sidney Kimmel Comprehensive Cancer Center at John Hopkins - Baltimore
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Cancer Institute - Detroit
- Henry Ford Health Providence Southfield Hospital - Southfield
California
- UCSF Fresno - Clovis
- UCLA - Santa Monica
Florida
- Memorial Healthcare System - Hollywood
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute Emory University - Atlanta
- City of Hope Cancer Center - Newnan
Connecticut
- Yale University School Of Medicine - New Haven
Delaware
- Medical Oncology Hematology Consultants, PA - Newark
Idaho
- Kootenai Health - Coeur d'Alene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06208150
The ClinicalTrials.gov registry entry for NCT06208150 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 795 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (46% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Teclistamab is the first listed.
NCT06208150 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Maryland, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT06208150 about?
NCT06208150 is a clinical study titled "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide". The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
What is the current status of trial NCT06208150?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2024-01-22. Estimated completion is 2028-03-31.
What conditions does trial NCT06208150 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06208150?
The interventions under investigation include: Teclistamab (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG), Talquetamab (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT06208150?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06208150 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.